Suzhou-based CD Biopharma, a fast-growing biotech company in the clinical stage, has been approved by the FDA for its CD-001 Investigational New Drug (IND) application, marking the start of a phase I human trial...
InnoCare Pharma, a top biopharmaceutical company specializing in cancer and autoimmune disease treatments, declared the approval of the Investigational New Drug (IND) to carry out a clinical trial of ICP-248, a B-cell lymphoma-2 (BCL2) inhibitor...
Stealth BioTherapeutics Inc., a biotech company in clinical stage, and Friedreich’s Ataxia Research Alliance (FARA) have announced that Stealth has received the Kyle Bryant Translational Research Award from FARA to study SBT-589 in Friedreich’s...
Efforts to replace medical inhalers with near-zero emission alternatives have advanced, as AstraZeneca announced the completion of the clinical program for a new propellant with 99.9% lower Global Warming Potential (GWP) than those used in current...
Sun Pharma and Israel-based Moebius Medical announced that the USFDA has granted fast track designation (FTD) to their novel non-opioid therapy, MM-II, designed to address osteoarthritis knee pain. This designation allows for an expedited review p...
.JPG)
Nxera Pharma Co., Ltd. is set to get a US$35 million payout from Neurocrine Biosciences (‘Neurocrine’) for the Phase 2 trial success with NBI-1117568 (NBI-‘568) in adults with schizophrenia, as disclosed on 28 August 2024. Recognition of the US$35...
Shilpa Medicare has effectively finished its phase 1 clinical trial for its leading product, sRbumin, a recombinant human albumin 20% (rHA). Human serum albumin is crucial for different medical interventions, including fluid replacement therapy...
On Tuesday, Bharat Biotech announced that its oral cholera vaccine has successfully completed a late-stage trial and is preparing for a global launch, with plans to produce up to 200 million doses annually. The vaccine, named Hillchol, has receive...
Alkermes plc has commenced the Vibrance-2 study, which is a phase 2 clinical trial assessing the safety and effectiveness of ALKS 2680 versus placebo in adult patients with narcolepsy type 2 (NT2). ALKS 2680 is a new, under investigation, oral...
Vimgreen Pharmaceuticals, a research-based pharmaceutical company specializing in adenosine signaling modulation, shared that they have finished enrolling participants in a phase 2 clinical trial for VG081821AC, a new drug for early-to-mid stage...
, CDSCO.jpg)
